Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 V564F |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 fusion FGFR2 V564F | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on Truseltiq (infigratinib) treatment (PMID: 28034880). | 28034880 |
FGFR2 fusion FGFR2 V564F | intrahepatic cholangiocarcinoma | predicted - sensitive | RLY-4008 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RLY-4008 treatment led to tumor regression in a cell line xenograft model of intrahepatic cholangiocarcinoma harboring an FGFR2 fusion and FGFR2 V564F (Cancer Res 2021;81(13_Suppl):Abstract nr 1455). | detail... |